# About bigtimepeptides

> About bigtimepeptides — Growth Hormone Axis Research — About bigtimepeptides: an independent literature digest on three Growth Hormone Axis research peptides — sermorelin, tesamorelin, and ipamorelin — how it's built and what it isn't.

**GROWTH HORMONE AXIS / COLOPHON**

A citation-anchored account of three GHRH- and ghrelin-receptor peptides — sermorelin, tesamorelin, and ipamorelin — and how far the evidence for each one actually reaches.

## What this site covers

bigtimepeptides tracks three of the most-studied names in growth-hormone-axis research: sermorelin, tesamorelin, and ipamorelin. All three eventually push the same downstream biology — a pulse of the body's own growth hormone from the pituitary gland — but they get there through two different receptor mechanisms, and they sit at very different points on the evidence ladder. Tesamorelin, the lead compound on this site, is the only one with an active FDA approval; sermorelin has a real if older human trial record and a history of prior approval; ipamorelin's confirmed human evidence is the thinnest of the three, despite being widely discussed in research communities. Each compound gets its own page, a comparison page lines all three up side by side, and one shared reference list gathers every source drawn on across the site.

## How this site works

Every factual claim on this site traces back to the published, peer-reviewed record — clinical trials, meta-analyses, regulatory safety monographs, and structured literature reviews, gathered with DOIs and PubMed links on the references page. Findings are reported in the specific population and trial design where they were actually studied, not generalized beyond that — a Phase 2 trial in 114 surgical patients is reported as exactly that, not extrapolated into a general claim. Where community and forum reports describe effects that haven't been measured in controlled trials, this site labels them explicitly as anecdotal, not clinical evidence, and never attaches a dose to them.

## A note on regulatory status

Regulatory status for compounded and research peptides moves — FDA's Section 503A bulk-substances list, the Pharmacy Compounding Advisory Committee's periodic reviews, and WADA's Prohibited List are all revised periodically. This site describes the status as understood at time of writing and notes where a compound's compounding-access category or approval history has recently changed; it isn't a substitute for checking current guidance before making any decision.

## What this site is not

bigtimepeptides is not a pharmacy, clinic, telehealth platform, or vendor. Nothing here is sold, sourced, or brokered — no peptide, no research chemical — and no compounding pharmacy or supplier pays for space on this site. No clinician is on staff; nothing is diagnosed, and no dose, schedule, or route is recommended for any person. Tesamorelin is a prescription medicine reachable only through a licensed provider, for its specific approved indication. Sermorelin, while previously approved, is now compounded rather than sold as a branded drug. Ipamorelin has never been approved anywhere and is sold only as a research chemical, outside the FDA's oversight of drug purity, potency, and safety. Anyone considering any of these compounds for any reason should take that decision to a licensed clinician in their own jurisdiction. Corrections, citation notes, or newly published research can be sent through the [contact page](/contact).

---

bigtimepeptides is an independent research digest on the growth-hormone axis — not a pharmacy, not a clinic, and not a source for any of the compounds it writes about.